source
- ICER report finds median launch drug prices jumped 24% between 2022 and 2025The Institute for Clinical and Economic Review released a new analysis showing that the median list price of newly launched drugs increased by 24% from 2022 to 2025. The report also notes that net…
- Pfizer halts Phase 2 trial of PF-06835375 in primary immune thrombocytopeniaPfizer announced that it is stopping its Phase 2 study of the experimental program PF-06835375, which was being evaluated in patients with primary immune thrombocytopenia, a rare autoimmune blood d…